The Austrian Society of Hypertension has published recommendations for treating patients with arterial hypertension with Renal Denervation (RDN), an interventional method, investigated recently in randomized, sham-controlled trials.

Renal Denervation is now supported by the 2024 ESC Guidelines

Renal Denervation (RDN), a clinical option for hypertensive patients, is listed in Austria as of January 2025. This allows hospitals to offer it to their patients on a larger scale. Patients profit from this allways-on effect for lowering elevated blood pressure resistant to optimal drug therapy (according to ESH 2023 guidlines)

conditions for a second working contract under the EU legislation 2019/1152 has now been clarified for Austria. A WIN-WIN-WIN situation for stakeholders in medical device Go-To-Market sales models.

This week, the first case of uRDN therapy was successfully performed in Austria

mlm medtech GmbH has been registered on Dec. 15th 2023 in Vienna, Austria. It offers sales and marketing of medical devices for cardiology and diabetes.

www.neurovalens.com gained FDA approval for its MODIUS device

A novel interventional method for successfully treating hypertension has been submitted by two main Austrian hospitals.

Over 10.000 accurate deliveries within last 6 months